CD24 antibody blockade

CD24 antibody blockade refers to the therapeutic strategy of using monoclonal antibodies to target and block Cluster of Differentiation 24 (CD24), a glycosylphosphatidylinositol (GPI)-anchored cell-surface glycoprotein. CD24 acts as an innate immune checkpoint and a potent "don't eat me" signal by interacting with sialic acid-binding immunoglobulin-like lectin 10 (Siglec-10) on macrophages and other immune cells, thereby inhibiting phagocytosis. Blocking this interaction disinhibits macrophages, promoting the phagocytic clearance of CD24-expressing cancer cells or senescent cells. This approach is being investigated primarily as a cancer immunotherapy for various solid tumors (such as ovarian, breast, and lung cancers) and is also being explored in preclinical models for clearing senescent bone marrow stromal cells (BMSCs) to address skeletal aging, as well as in myeloproliferative neoplasms (MPN) to restore neutrophil clearance.

Other names

anti-CD24 antibodyanti-CD-24 antibodyanti-CD 24 antibodyanti-CD24 monoclonal antibodyanti-CD-24 monoclonal antibodyanti-CD 24 monoclonal antibodyCD24 antibodyCD-24 antibodyCD 24 antibodyCD24 blockadeCD-24 blockadeCD 24 blockadeCD24 monoclonal antibodyCD-24 monoclonal antibodyCD 24 monoclonal antibodyCD24-blocking antibodyCD-24-blocking antibodyCD 24-blocking antibodymonoclonal anti-CD24 antibody